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Abstract Interaction between hypoxia and coagulation is important given the increased risk of
thrombotic diseases in chronically hypoxic patients who reside at sea level and in
residents at high altitude. Hypoxia alters the proteome of platelets favouring a
prothrombotic phenotype, but studies of activation and consumption of speciﬁc
coagulation factors in hypoxic humans have yielded conﬂicting results. We tested
blood from 63 healthy lowland volunteers acclimatizing to high altitude (5,200 m)
using thromboelastometry and assays of platelet function to examine the effects of
hypoxia on haemostasis. Using data from two separate cohorts of patients following
identical ascent proﬁles, we detected a signiﬁcant delay in clot formation, but increased
clot strength by day 7 at 5,200 m. The latter ﬁnding may be accounted for by the
signiﬁcant rise in platelet count and ﬁbrinogen concentration that occurred during
acclimatization. Platelet function assays revealed evidence of platelet hyper-reactivity,
with shortened PFA-100 closure times and increased platelet aggregation in response
to adenosine diphosphate. Post-expedition results were consistent with the normal-
ization of coagulation following descent to sea level. These robust ﬁndings indicate that
hypoxia increases platelet reactivity and, with the exception of the paradoxical delay in
thromboelastometry clotting time, suggest a prothrombotic phenotype at altitude.
Further work to elucidate the mechanism of platelet activation in hypoxia will be
important and could impact upon the management of patients with acute or chronic
hypoxic respiratory diseases who are at risk of thrombotic events.
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Introduction
Reports of arterial and venous thrombosis at high altitudehave
fuelled research testing thehypothesis that hypoxia provokes a
prothrombotic phenotype.1–4 Epidemiological data suggest a
30-fold increased riskof strokeor venous thrombosis following
prolonged sojourn at altitudes greater than 3,000m.5 Further-
more, individuals from a high altitude area (> 3,000 m) who
were admitted to hospital had a stroke incidence of 13.7/1,000
versus 1.05/1,000 in the wider population and notably almost
all of these events occurred in patients younger than 45 years
who lacked other cardiovascular risk factors.6More controver-
sially, hypoxaemia has been proposed as a signiﬁcant factor in
the increased risk of thrombosis in air travellers, as the cabin
pressure inmost aircraft is equivalent to an altitude of 2,000 to
2,500 m.7,8 The risk of a venous thromboembolism approxi-
mately doubles following a long-haul ﬂight (>4 hours), the so-
called economy class syndrome,9 but studies investigating
whether the degree of hypoxia experienced in an aircraft cabin
alters markers of activated coagulation pathways have gener-
ated inconsistent results.10–13 Importantly, the evidence of
interplaybetweenhypoxia and coagulationextends topatients
who reside at sea level. Diseases characterized by chronic
hypoxaemia carry an increased risk of arterial and venous
thrombosis.14–16 Therefore, at both high and low altitudes,
greater understanding of the interaction between hypoxia and
haemostasis is important and may inform patient manage-
ment strategies.
Field studies investigating coagulation at altitude are inher-
ently difﬁcult. Cold, exercise, heterogeneous ascent proﬁles,
and sensitivity of equipment and assays potentially compro-
mise conclusions. We aimed to reduce these problems by
conducting near-patient tests in a high-altitude laboratory
setting after a controlled non-exertional ascent. In two sepa-
rate groups of patients, we investigated the effects of hypo-
baric hypoxia on thromboelastometry and platelet function,
testing the hypothesis that hypoxia activates coagulation.
Methods
Data are included from two expeditions, Apex 2 and Apex 4.
Both studies were approved by the Lothian Research Ethics
Committee and all participants gave written informed con-
sent. Participants received no remuneration for their role in
the research.
Ascent Proﬁle and Sample Collection
All patientswere resident at altitudes less than 600m and had
not been to heights greater than 1,500 m in the 3 months
preceding the study. Patients ﬂew to La Paz, Bolivia (3,600m),
and spent 4 or 5 days there before ascending for 90minutes by
road to the Chacaltaya Laboratory (5,200 m). ►Fig. 1A shows
the ascent proﬁle of the expeditions and the timing of blood
sampling. Sea-level samples were taken before the expedition
onApex4but after the expeditiononApex2. Bloodwasdrawn
using a 21-gauge needle, with minimal tourniquet pressure
and collected in sterile tubes (Sarstedt, Nümbrecht, Germany)
containing sodium citrate or EDTA. Peripheral arterial oxygen
saturation (SpO2) was measured for each patient prior to
departure and on each day of investigation using a pulse
oximeter (Masimo Rad 5, Irvine, United States). Patients self-
recorded symptoms of acute mountain sickness (AMS) using
the Lake Louise self-assessment score (LLS)17 and a visual
analogue scale symptom score.18
Fig. 1 Oxygen saturation, haematocrit, haemoglobin concentration
and platelet count on two expeditions (Apex 2 and Apex 4) to 5,200m.
(A) Patients on both expeditions were exposed to an identical ascent
proﬁle. Timing of blood samples at altitude are indicated by shaded
arrows (Apex 2) and open arrows (Apex 4). (B, C) Peripheral oxygen
saturations measured at rest on Apex 2 (C) and Apex 4 (B). (D–I) Blood
was collected at the time points indicated on Apex 4 (D, F, H) and Apex
2 (E, G, I), and haematocrit (D, E), haemoglobin concentration
(F, G) and platelet count (H, I) were analysed using automated clinical
analysers. Data are mean (horizontal bars)  SEM. SL, sea level. Apex
2 data points are represented by closed circles; Apex 4 data points are
represented by open circles. (B, D, F, H)  p < 0.0001 using paired
t-tests. (C, E, G, I) p < 0.005 versus SL pre-expedition, #p < 0.005
versus SL post-expedition, ¶p < 0.005 versus day 1 at 5,200 m using
paired t-tests corrected for multiple comparisons using Bonferroni
method, p < 0.005 accepted as signiﬁcant. (B) Signiﬁcance level of
p < 0.0083 or (D, F, H) p < 0.05 accepted as signiﬁcant.
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Thromboelastometry Analysis
Thromboelastometry was performed on Apex 2 using a
ROTEG05 (Pentapharm GmbH, Munich, Germany) and on
Apex 4 using a ROTEM Pactem analyser (TEM International
GmbH, Munich, Germany). Each citrated blood sample was
assayed within 60 minutes of venepuncture using activators
of the extrinsic (EXTEM: tissue factor) and intrinsic (INTEM:
phospholipid and ellagic acid) pathways and results were
recorded digitally. FIBTEM (cytochalasin D and tissue factor)
tests were performed on each blood sample on Apex 4.
Internal quality control tests were also recorded at regular
intervals throughout the sampling period and values fell
within the accepted ranges at all altitudes. Each rotational
thromboelastometry (ROTEM) test requires 300 µL of
citrated whole blood. Tests were run to obtain an A20 clot
amplitude at 20minutes, and results of clotting time (CT) and
clot formation time (CFT, the time from the start of clot
formation to thromboelastometry trace amplitude of
20 mm) were recorded.
Platelet Function Analysis
On Apex 2, citrated bloodwas analysed, within 5minutes, by
a PFA-100 analyser (Siemens Diagnostics, supplied by Sys-
mex UK Ltd.). PFA-100 closure time was recorded using
collagen-epinephrine cartridges. On Apex 4, bloodwas taken
into a Hirudin tube (Roche Diagnostics, UK) and Multiplate
analysis was conducted exactly 20 minutes following vene-
puncture. Platelet activationwith thrombin receptor activat-
ing peptide (TRAP, 32 μM), collagen (3.2 μg/mL) and
adenosine diphosphate (ADP, 20 μM) stimulation was per-
formed and quantiﬁed using the area under the curve of
arbitrary aggregation units against time (AUC).
Full Blood Count Analysis
Full blood count (FBC) analysis was performed at sea level
using a KX21-N (Sysmex, UK) within 24 hours of blood
collection in EDTA. FBC was measured in La Paz, Bolivia,
using a Micros 60 (Horiba, Northampton, UK) 30 hours after
blood collection at 5,200 m. The EDTA tubes had been stored
and transported upright at 20°C.
Plasma Preparation
Citrated venous blood (10 mL) was centrifuged immediately
at 2,500 g for 15minutes and the supernatant pipetted into a
10-mL propylene centrifugation tube. Plasma was centri-
fuged again at 2,500 g for 15 minutes (Labofuge 200, Kendro
Laboratory Services, Herts, UK). Plasma aliquots of 500 µL
were pipetted into 1 mL propylene aliquot tubes, stored
vertically, snap frozen to80°C and transported on dry iceby
specialist international courier to a 80°C storage facility in
the UK. Plasma ﬁbrinogen, prothrombin time (PT) and
activated partial thromboplastin time (aPTT)weremeasured
in a NHS haematology laboratory.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 6.0.
The normality of datasets was assessed using Kolmogorov–
Smirnov tests and paired t-tests were used to compare differ-
ences in parameters between sample days. Comparisons of
sea-level results versus each time point at altitude and
between time points at altitude were made (e.g. for measures
recorded on four occasions, six comparisons were made) and
p-valuewas adjusted by the Bonferroni method. Therefore, for
measures recorded on four occasions, p < 0.0083 (0.05/6)was
accepted as signiﬁcant. Relationships between continuous
variables were examined bymeans of individual scatter-plots
andwhere these graphswere suggestive of at least averyweak
linear trend, Pearson’s correlation coefﬁcientswere calculated
and R-squared provided as a measure of the strength of the
corresponding linear trends.
Results
Data are included from63patients across two expeditions and
comparative demographics are presented in ►Table 1. On
Apex 2, seven patients were evacuated from the laboratory
at 5,200 m with symptoms of AMS after the ﬁrst altitude
sample had been collected. Data were included until evacua-
tion. No patients were on medication to treat AMS, but they
were permitted to take paracetamol. A further 13 measure-
mentswere lost in different patients on different test days (10
onApex 2, 3 onApex 4) due to logistical or technical problems.
Profound hypoxaemia was observed from day 1 at 5,200 m
and persisted for the duration of the sojourn at altitude
(►Fig. 1B, C). Haematocrit rose signiﬁcantly after 4 days of
acclimatization at 3,600m and rose further during the sojourn
at 5,200 m (►Fig. 1D, E), with a corresponding increase in
haemoglobin concentration (►Fig. 1F, G). Platelet count roseby
day7at5,200monbothexpeditions (►Fig. 1H, I).Haematocrit,
Table 1 Comparative demographic data of the study populations
on Apex 2 and Apex 4 expeditions, including prevalence of AMS at
5,200 m
Apex 2 Apex 4
Number of patients 41 22
Male/Female, % 61/39 54/46
Mean BMI
pre-expedition (SD)
22.87 (2.67) 22.31 (2.82)
Median age (range) 21 (19–30) 19 (18–27)
Prevalence AMS
Day 1 65% —
Day 3 54% 46%
Day 5 21% 33%
Day 7 13% 21%
Median LLS (range)
Day 1 4 (0–10) —
Day 3 3 (0–13) 3 (0–7)
Day 5 1 (0–8) 2 (0–8)
Day 7 1 (0–6) 1 (0–9)
Abbreviations: AMS, acute mountain sickness; BMI, body mass index
(kg/m2); LLS, Lake Louise score; SD, standard deviation.
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haemoglobin concentration and platelet count had returned to
normal by the time Apex 2 post-expedition sea-level samples
were obtained (►Figs. 1E, G, I).
The traditionalmeasures of coagulation, aPTT and PTwere
not signiﬁcantly different compared with sea-level values
(►Fig. 2A, D). However, thromboelastometry demonstrated
that the initiation of clotting (CT)was delayed at altitude. The
delay occurred upon activation of blood with either ellagic
acid (INTEM;►Fig. 2C) or tissue factor (EXTEM; ►Fig. 2E, F),
although on the Apex 4 expedition, the increase in INTEMdid
not reach statistical signiﬁcance (►Fig. 2B). CT was signiﬁ-
cantly prolonged compared with the post-expedition sea-
level values at all time points on Apex 2 (►Fig. 2C, F). Modest
but signiﬁcant correlations were observed between haema-
tocrit (pooling values from sea level and day 7 at 5,200 m)
and both INTEM CT (r2 0.4, p < 0.0001) and EXTEM CT
(r2 0.29, p < 0.0001) on Apex 2 (►Fig. 2G, H) and Apex 4
(haematocrit vs. INTEM CT (r2 0.17, p ¼ 0.007) or versus
EXTEM CT (r2 0.41, p < 0.0001; Suppl 1A, B). No change in
CFT was observed on either expedition following intrinsic
(INTEM) activation (Suppl 2A, B). While there was a signiﬁ-
cant reduction in CFT following tissue factor (EXTEM) acti-
vation on days 1 and 7 on Apex 2 (Suppl 2D), this was not
mirrored by the Apex 4 data (Suppl 2C).
EXTEM trace amplitude at 20 minutes (A20) was signiﬁ-
cantly greater on day 7 at 5,200 m on both expeditions
(►Fig. 3C, D) and INTEM A20 was greater by day 3 at
5,200 m on Apex 2 (►Fig. 3B). The increase in INTEM A20 on
Apex 4 did not reach statistical signiﬁcance (►Fig. 3A). Platelet
count is an important determinant of clot strength and we
detected signiﬁcant, although weak, correlations between pla-
telet count and EXTEM A20 on both expeditions (►Fig. 3E, F).
FIBTEM uses cytochalasin D to inhibit platelet function and
assesses ﬁbrin clot strength in the absence of platelet
Fig. 2 Hypobaric hypoxia prolongs clotting time (CT) assessed by thromboelastometry. (A, D) aPTT and PTwere measured using citrated plasma
collected on Apex 4. Whole blood was analysed using thromboelastometry on Apex 4 (B, E) and Apex 2 (C, F) using the coagulation activators,
ellagic acid (INTEM)(B, C) or tissue factor (EXTEM)(E, F). CT is the time from the start of the assay until the thromboelastometry trace reaches an
amplitude of 2 mm, considered to be the start of clot formation. Data are mean (horizontal bars)  SEM. (A–F) p < 0.001, p < 0.0001
using paired t-tests corrected for multiple comparisons using the Bonferroni method, p < 0.0083 accepted as signiﬁcant. (G, H) Correlations
between haematocrit (pooling values from sea level and day 7 at 5,200 m) and INTEM CT (G) and EXTEM CT (H) on Apex 2. Apex 2 data points are
represented by closed circles, Apex 4 data points are represented by open circles. Reference ranges for thromboelastometry parameters are
provided as dashed lines on each graph.51
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activation. Fibrinogen levels were signiﬁcantly elevated on
day 3 and day 7 at 5,200 m compared with sea level
(►Fig. 4A). Consistent with this ﬁnding, FIBTEM A20 was
signiﬁcantly increased by day 7 (►Fig. 4B) and ﬁbrinogen
levels correlated with FIBTEM A20 (►Fig. 4C).
Multiplate assays demonstrated no signiﬁcant changes in
platelet aggregation upon stimulation with either TRAP or
collagen (►Fig. 5A, B). Aggregation in response to ADP was
signiﬁcantlygreateronday7at5,200m(►Fig. 5C).As a further
indication of platelet reactivity, PFA-100 closure times, using
collagen-epinephrine cartridges, were profoundly reduced
from day 1 at 5,200 m and remained low during the 7-day
altitude sojourn, compared with post-expedition sea-level
values and published reference ranges (►Fig. 5D).19
Discussion
Hypoxia, whether local or systemic, frequently complicates
thromboembolism, but the role it plays in altering haemostasis
is poorly understood. Using near-patient tests on healthy
volunteers in an extreme hypoxic environment, we have
Fig. 3 Thromboelastometry measurements demonstrate an increase
in clot strength at 5,200 m. Whole blood was analysed using
thromboelastometry on Apex 4 (A, C) and Apex 2 (B, D) using INTEM
(A, B) or EXTEM (C, D). A20 is the trace amplitude after 20minutes and
is a measure of clot strength. Data are mean (horizontal bars)  SEM.
(A-D) p < 0.001, p < 0.0001 using paired t-tests corrected for
multiple comparisons using the Bonferroni method, p < 0.0083
accepted as signiﬁcant. (E, F) Correlations between platelet count
(pooling values from sea level and day 7 at 5,200 m) and EXTEM A20
on Apex 2 (E) and Apex 4 (F). Apex 2 data points are represented by
closed circles; Apex 4 data points are represented by open circles.
Reference ranges for thromboelastometry parameters are provided as
dashed lines on each graph.51
Fig. 4 Increased ﬁbrinogen and ﬁbrin-dependent clot strength at altitude.
(A) Fibrinogen levels were measured on Apex 4 at the time points indicated.
(B)Wholeblood thromboelastometry analysis ofA20usingFIBTEMonApex4.
Data aremean (horizontal bars)  SEM. p < 0.05, p < 0.01, p < 0.001
using paired t-tests corrected for multiple comparisons using the
Bonferroni method, (A) p < 0.016 or (B) p < 0.0083 accepted as signiﬁcant.
(C) Correlation between plasma ﬁbrinogen concentration and FIBTEM
A20 (pooling values from sea level and day 7 at 5,200 m). Reference
ranges for thromboelastometry parameters are provided as dashed
lines on each graph.51
Fig. 5 Evidence of increased platelet reactivity at 5,200m. Platelet function
was assessed on Apex 4 using Multiplate electrode aggregometry assays on
whole blood activated by (A) thrombin receptor activating peptide (TRAP),
(B) Collagen (COL) or (C) adenosine diphosphate (ADP). Area under the curve
(AUC) represents the degree of platelet aggregation over time. (D) Platelet
function was assessed on Apex 2 using a PFA-100 device and collagen-
epinephrine cartridges. Increased platelet reactivity reduces closure time.
Data are mean (horizontal bars)  SEM. p < 0.01, p < 0.00001 using
paired t-tests corrected for multiple comparisons using the Bonferroni
method, (C)p < 0.016or (D)p < 0.0083acceptedas signiﬁcant. Apex2data
pointsare representedbyclosedcircles;Apex4datapointsare representedby
open circles.
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gathereduniquedatadescribingaltitude-inducedalterations in
coagulation. Data from two separate expeditions to high alti-
tude revealed an increase in the clotting time at 5,200mwhen
compared with pre-expedition or post-expedition sea-level
values, as measured by thromboelastometry. Although there
was a latency in clot formation, we found evidence of an
increase in clot strength, indicated by an increase in amplitude
of the TEM trace 20 minutes after clot was ﬁrst detected.
Furthermore, after 3 days at altitude, there was an increase
in plasma ﬁbrinogen concentration and this was associated
with an increase in ﬁbrin-formed clot strength. Finally, using
two different measurements of platelet function, we revealed
an increase in platelet reactivity at high altitude in response to
ADP and collagen-epinephrine stimulation.
Rotational thromboelastometry allows a measurement of
global haemostatic function in whole blood samples. The
technique analyses the dynamics of clot formation and gives
information on the interaction of platelets, clotting factors
and ﬁbrinogen to generate a graphical depiction of the
coagulation process. Unlike speciﬁc blood component assays,
thromboelastometry examines the complete interaction
between plasma constituents revealing the net conse-
quences of abnormalities affecting the formation of the
clot. Despite our apparent paradoxical ﬁndings of a latency
in clot formation but an increase in clot strength, our results
are remarkably consistent with previous work performed at
altitude. Using a similar method, thromboelastography
(TEG), the Caudwell Everest expedition assessed coagulation
at 5,300m in 17 healthy volunteerswho ascended to thebase
camp of Mount Everest over 13 days.20 Reaction (R) time and
coagulation (K) time (comparable to CT and CFT, respec-
tively) were both increased compared with sea level on
arrival at 5,300m, and the α-angle was decreased.20Modesti
et al conducted a similar study using ROTEM at Everest base
camp (5,300m) with 47 volunteers and discovered increases
in CT, CFT and ﬂattened α-angle using an INTEM assay.21
Consistent with our ﬁndings, a signiﬁcant increase in MCF
was observed after a 10-day sojourn at Everest base camp.21
Interestingly, signiﬁcantly shorter CFT and higher MCF
values were found in patients who developed AMS during
that expedition compared with those who did not.21
Although the study by Modesti et al was conducted at a
similar altitude to our study, it should be noted that the
ascent proﬁle in our studywasmore rapid. These differences
could explain why we did not observe any association
between TEM parameters and AMS (data not shown).
The prolongation of CT described here and by others20,21
suggests a delay in clot formation at altitude. Prolonged
TEM CT is described in the context of clotting factor
deﬁciency.22,23 However, studies have shown either no
change or increases in the level of plasma clotting factors
at altitudes of greater than 4,500 m.24,25 Martin et al
proposed that the altitude-induced prolongation of TEG, R
time, might involve the inhibition of clotting factor activity
by nitric oxide (NO).20 There is evidence of increased NO
formation in lowlanders ascending to high altitude,26 while
ex vivo administration of nitrite (a NO precursor) to hypoxic
blood from healthy volunteers increased R time.27 However,
NO has also been shown to reduce clot strength,27,28 a
ﬁnding inconsistent with our results. Changes in blood pH
are also known to alter CT, but while acidiﬁcation of blood
was previously demonstrated to prolong CT, induced alka-
losis had no effect.29 Therefore, the hypocapnic alkalosis
that occurs on ascent to altitude would not explain our
ﬁndings. Interestingly, a similar delay in coagulation has
been reported in patients with congenital cyanotic heart
disease (CCHD), a population with hypoxaemia and high
haematocrit.30 A study of 75 patients with CCHD showed a
correlation between haematocrit and R time assessed by
TEG,30 a ﬁnding mirrored by the modest but signiﬁcant
correlations between haematocrit and CT results on both
Apex expeditions. Nonetheless, it is possible that the
observed changes in TEM CT are due to a relative dilution
of coagulation factors within the whole blood sample,
caused by the rise in haematocrit. This phenomenon has
been simulated by ex vivo addition of autologous red cells to
elevate the haematocrit of blood from healthy volunteers31
and converse effects are observed in patients with ane-
mia.32 Moreover, it is notable that we did not ﬁnd changes
in conventional clinical measurements of coagulation
(PT and aPTT) performed on citrated plasma and therefore
independent of haematocrit. Experimental alteration of
haematocrit at sea level and at high altitude would be
necessary to conﬁrm whether the observed changes in
clot latency were due to hypoxia or haematocrit.
In contrast to the results from patients with CCHD,30,31we
observed a rise in clot strength as assessed by TEM trace
amplitude after 20 minutes. Indeed, elevated haematocrit
was associated with reduced maximum clot ﬁrmness (MCF)
assessedbyEXTEMorFIBTEMinCCHDpatientsor followingex
vivo manipulation of haematocrit levels.31 Other factors con-
tributing to clot strength assessed by TEG include ﬁbrinogen
levels and platelet count33,34 and it is possible that differences
in these parameters explainwhyclot strength increased in our
study despite the rise in haematocrit. Notably, patients with
CCHD tend to have lower platelet counts than healthy volun-
teers31 and we observed increases in both platelet count and
ﬁbrinogen in our patients over time at 5,200 m. Furthermore,
we detected signiﬁcant correlations between platelet count
and EXTEM A20 on both expeditions. The addition of FIBTEM
and ﬁbrinogen measurements on the Apex 4 expedition
allowed us to determine whether platelet count alone
accounted for the increased A20, as cytochalasin D eliminates
theplatelet componentofclot strength.However, A20wasalso
elevated when assessed by FIBTEM on the Apex 4 expedition
and therefore the increase in EXTEMA20 is likely to be due to a
combination of increases in platelet count and plasmaﬁbrino-
gen concentration.
Our ﬁnding of increased platelet count at altitude on both
expeditions is notable given inconsistent historical results.35,36
The rise in platelet count lagged temporally behind that of
haematocrit, suggesting that it was not simply a consequence
of haemoconcentration. The potential importance of platelet
count in the context of hypoxaemia is indicated by the inde-
pendent association between higher platelet counts and
increased mortality in patients with lung disease who reside
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at sea level.37 In addition, we found evidence of increased
platelet reactivity at altitude. PFA-100 closure time was sig-
niﬁcantly shorter than post-expedition sea-level results and at
or below the lower limit of published reference ranges from
day 1 at 5,200 m and remained low for the duration of the
altitude sojourn. Our results are consistent with a study
investigating platelet function in 24 patients known to be
susceptible to high altitudepulmonaryoedema and 10healthy
controls.38 Lehmann et al described a reduction in collagen-
epinephrine closure times of 27% on arrival at 4,559 m after a
2-day ascent and found nodifference in closure times between
HAPE-susceptible patients and controls.38 Interestingly, the
study by Lehmann et al found a signiﬁcant fall in platelet count
on arrival at altitude and attributed this to platelet aggregation
and consumption secondary to hypoxia-induced activation.
A key difference between our study and that of Lehmann et al
was the nonexertional ascent on Apex expeditions, compared
with several hours of hiking. While it is possible that exercise
may have inﬂuenced platelet numbers, the similarities in
platelet reactivity suggest that the observed differences in
platelet counts are not due to aggregation.However,we cannot
exclude the possibility of a transient, unmeasured, drop in
platelet count in our patients during the initial ascent to
3,600 m on arrival in La Paz.
To explore how hypoxia alters platelet reactivity, we
performed further tests of platelet activation on Apex 4,
screening different platelet agonists using Multiplate impe-
dance aggregometry assays. These revealed a speciﬁc
increase in platelet aggregation in response to ADP by
day 7 at 5,200 m. Consistent with this ﬁnding, platelets
isolated from rats exposed to hypoxia for 6 hours also display
increased aggregation in response to ADP, associated with
increased ATP release and increased surface expression of
platelet activation markers.39 Indeed, the study by Tyagi et al
demonstrated important hypoxia-induced alterations in the
platelet proteome, including induction of platelet-derived
tissue factor and ﬁbrinogen and suppression of antithrom-
botic proteins.39 Calpain proteases were identiﬁed as impor-
tant mediators of hypoxia-induced platelet hyper-
responsiveness and are known to be activated by increased
intracellular Ca2þ,40 a downstream consequence of P2Y1
receptor activation by ADP. Although this proposed interac-
tion between ADP and calpains requires further investiga-
tion, the alteration of the hypoxic platelet proteome adds
credibility to our observed changes in platelet function at
altitude and suggests a possible mechanism for the rise in
ﬁbrinogen concentration at altitude.
Multiplate results may be affected by platelet count and
haematocrit.41,42 However, suspensions of increasing platelet
counts provoked a nonspeciﬁc increase in aggregation in
response to several agonists rather than a speciﬁc response
toADPalone.41 Furthermore, the early increase in haematocrit
(►Fig. 1E) preceded the signiﬁcant rise in ADP-induced plate-
let aggregation, which did not occur until day 7 at 5,200 m. A
rise in haematocrit can also reduce the closure timemeasured
by PFA-100.43 However, we found no correlation between the
rise in haematocrit on ascent to altitude and change in closure
time (data not shown). In addition, the magnitude of the
reduction in closure time exceeds that which would be
expected by the observed rise in haematocrit.44
This work has several limitations. First, while we provide
evidence of hypercoagulability in the form of increased TEM
clot strength and platelet activation, how these parameters
might relate to risk of subsequent thrombotic events is not
clear. Studies using TEG have indicated a possible relation-
ship between clot strength and thrombosis risk in the con-
text of surgery,45 functional outcome following stroke46 and
recurrent ischaemic events after percutaneous coronary
intervention.47 While there is agreement between TEG and
ROTEM measures of clot strength,48 direct extrapolation of
the quantiﬁed risk from TEG parameters to ROTEM is not
possible and there are few published studies investigating
links between ROTEM measures of clot strength and throm-
botic risk. Hincker et al reported a relationship between
preoperative ROTEM parameters and postoperative risk of
thromboembolic complications following cardiac surgery.49
Patients who developed thromboembolic complications had
signiﬁcantly higher preoperative EXTEM MCF values, but
notably other parameters that might indicate hypercoagul-
ability were also abnormal (shorter CFT and steeper
α-angle). The odds ratio for developing a postoperative
complication if EXTEM MCF was outside the normal range
was 4.65. However, only 4 of the 30 patients who developed
complications fulﬁlled this criterion, implying that values
need not lie outside the normal range. Indeed, it is plausible
that there is a more continuous relationship between clot
strength and thrombotic risk, but further work using TEM is
required to establish such a link. Second, the applicability of
our ﬁndings to high altitude dwellers or patients with
chronic respiratory disease at sea level is also unclear, and
studies during longer term hypoxic exposuremay havemore
direct relevance to the increased risk of thrombotic events in
such groups. Finally, although our post-expedition data
suggest that the assessed coagulation parameters normalize
on return to sea level, only assessment of pre-expedition and
post-expedition data from the same cohort would provide
evidence to conﬁrm this conclusion. Moreover, as it has
recently been demonstrated that short-term acclimatization
to hypoxia has a prolonged impact on murine leukocyte
transcriptional responses and metabolism on reexposure
to acute hypoxia,50 it would also be of interest to collect
data after re-ascent to altitude in acclimatized volunteers.
In conclusion,we demonstrate evidence of increased plate-
let reactivity and increased clot strength inwholebloodassays
inhealthyvolunteersexposedtoaltitudehypoxia.The increase
in clot strengthmay be explained by rises in platelet count and
ﬁbrinogen while the recent discovery of hypoxia-induced
changes in the platelet proteome39 may provide insight into
our observations of increased platelet reactivity. Whether our
results indicate an increased risk of thrombotic events at
altitude is not clear and requires further study. Nonetheless,
our ﬁnding of increased platelet reactivity at high altitude has
potential implications for patientswho reside at sea levelwith
acute or chronic diseases caused or complicated by hypoxia
and known to be at risk of thrombotic events. Understanding
themechanisms driving platelet activation and clot behaviour
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in hypoxia might impact upon treatment of such patients at
sea-level, in addition to increasing our understanding of
altitude-related thromboses.
What is known about this topic?
• Epidemiological evidence suggests that exposure to
high altitude is associated with an increased risk of
thrombotic events.
• Published data from assays of blood coagulation have
not conclusively supported a prothrombotic pheno-
type at high altitude.
What does this paper add?
• In two separate cohorts of healthy volunteers ascend-
ing to high altitude, we report evidence of altered
haemostasis.
• We found evidence of increased clot strength, assessed
by thromboelastometry, and evidence of increased
platelet reactivity after 7 days at 5,200 m.
• Our data imply that hypoxia alters platelet reactivity, a
ﬁnding of importance to those ascending to high
altitude which may also be of relevance to patients
who reside at sea level with diseases characterized by
acute hypoxia.
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